Find Clinical Trials

Inclusion Criteria: 1. Diagnosed with depression/anxiety; 2. Continued use of SSris and SNris for six months prior to study start; 3. Aged between 18 and 70; 4. Confirmed cardiovascular disease (such as chronic stable coronary heart disease, heart failure, cardiomyopathy, arrhythmia, valvular heart disease, cardiac surgery, cardiac intervention, ischemia with non-obstructive coronary artery disease, etc.); 5. The patients voluntarily participated in the study, signed a written informed consent, and were willing to cooperate with the follow-up. Exclusion Criteria: 1. currently has mania or hypomania, or a history of bipolar disorder and any mental disorders (current and previous); 2. organic brain injury, etc., or serious non-cardiovascular system diseases (such as advanced cancer); 3. Unable to participate in sports training or have drug contraindications; 4. Current alcohol, drug abuse, drug use or suicidal intent; 5. Patients who were receiving other doses of eligible drugs and other antidepressants were excluded from the trial; 6. Myocardial infarction \<2 weeks or unstable angina attack period; 7. Severe and uncontrolled arrhythmia; 8. Acute heart failure stage; 9. Severe and symptomatic obstruction of the outflow tract; 10. Acute deep vein thrombosis with or without pulmonary embolism; 11. Acute myocarditis, pericarditis or endocarditis; 12. Acute aortic dissection; 13. Intracardiac thrombus with high risk of embolism; 14. Massive pericardial effusion; 15. Those who fail to exercise adequately or refuse to sign informed consent.

Inclusion Criteria: * histologically proven breast cancer who have undergone conservative surgery * at least 3 inserted clips * age: from 18 years old to 50 years * at least one of the following risk factors: N1 disease, LVI, extensive intraductal component (\>25%), close margins (\<4 mm), non-hormone-sensitive disease, grading 3 * ECOG performance status \< 2 * adequate bone marrow (haemoglobin concentration \> 8 g/dl, white blood cell count \> 3000/mm3, platelet count \> 75000). Exclusion Criteria: * Previous chest radiation treatment * Bilateral breast cancer * Neoadjuvant chemotherapy * BMI \> 35 * Collagen diseases * Pregnancy or breastfeeding

Inclusion Criteria * Age ≥ 18 years of age * ECOG ≤ 1 * High-risk early stage triple negative breast cancer (TNBC), defined by ER≤10%, PR≤10% and HER2 negative (by IHC or FISH), per ASCO/CAP guidelines * Clinically ≥T1cN0, or any T, N1-2 * Plan to receive neoadjuvant chemotherapy and immune checkpoint inhibitor before surgery as standard-of-care treatment * Adequate organ function as defined in the following. Specimens must be collected within 14 days prior to the start of study treatment. * ANC ≥ 1,500/mm3 * Platelets ≥ 100,000/mm3 * Hemoglobin ≥ 9.0 g/dL. * Total serum bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \>1.5 x ULN * AST \< 3 x ULN * ALT \< 3 x ULN * Creatinine clearance ≥ 30 mL/min * INR or PT, aPTT \< 1.5 x ULN * Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test within 14 days of start of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Note: If egg harvesting was completed prior to enrollment, the pregnancy test may be falsely positive and the PI will assess and determine eligibility for these cases. * Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix B), not breastfeeding, and at least one of the following conditions applies: \-- Not a woman of childbearing potential (WOCBP) as defined in Appendix B OR Females of child-bearing potential must be willing to use effective contraception during study and for 120 days after the last dose. * Male participants: A male participant must agree to use a contraception as detailed in Appendix B of this protocol during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period. * Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. Exclusion Criteria * Evidence of metastatic disease. * Is currently participating in or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. * History of bleeding tendencies or coagulopathy and/or clinically significant bleeding symptoms or risk within 4 weeks prior to start of study treatment, including but not limited to: * Hemoptysis (defined as coughing up ≥ 0.5 teaspoon of fresh blood or small blood clots) Note: transient hemoptysis associated with diagnostic bronchoscopy is allowed. * Nasal bleeding/epistaxis (bloody nasal discharge is allowed) * Current use of prophylactic or full-dose anticoagulants or anti-platelet agents for therapeutic purposes that is not stable, in the opinion of the treating investigator, prior to start of study treatment is not allowed. The use of full-dose anticoagulants is permitted as long as the INR or activated partial thromboplastin time (aPTT) is within therapeutic limits according to the medical standard of the enrolling institution. * Poorly controlled hypertension with repeated systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy * Women who are or are planning to become pregnant or breastfeed * Known allergy to any of the components within the study agents and/or their excipients * Medical history and concurrent diseases * Autoimmune diseases * Any prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least three years * History of (non-infectious) pneumonitis that required steroids or has current pneumonitis * Active infection requiring systemic therapy * Known history of Human Immunodeficiency Virus (HIV) infection * Known history of active Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority * Known history of active TB (Mycobacterium tuberculosis) * History of unstable angina, myocardial infarction, congestive heart failure (New York Heart Association \[NYHA\] classification ≥ grade 2) or unstable vascular disease (eg, aortic aneurysm at risk of rupture, Moyamoya disease) that required hospitalization within 12 months prior to randomization, or other cardiac impairment that may affect the safety evaluation of the study drug (eg, poorly controlled arrhythmias, myocardial ischemia) * Prolongation of QTc interval \>480 msec * Prior allogeneic bone marrow transplantation or prior solid organ transplantation * History of esophageal gastric varices, severe ulcers, wounds that do not heal, abdominal fistula, intra-abdominal abscesses, or acute gastrointestinal bleeding within 6 months prior to start of study treatment * History of any grade arterial thromboembolic event, Grade 3 and above venous thromboembolic event, as specified in National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 12 months prior to start of study treatment * Acute exacerbation of chronic obstructive pulmonary disease within 4 weeks before start of study treatment * History of perforation of the gastrointestinal tract and/or fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to start of study treatment * Prohibited Treatments and/or Therapies * Other non-protocol specified anti-cancer therapy: systemic radiotherapy, immunotherapy, biologic, or hormonal therapy. tretinoin therapy, nitrosourea, mitomycin C, small molecule tyrosine kinase inhibitor therapy \--- Concomitant use of hormones for non-tumor-related conditions (e.g., insulin and hormone replacement therapy for diabetes mellitus) is acceptable * Any live vaccine within 30 days prior to the first dose of study drug and up to 120 days after the last dose. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed * Prior systemic therapy or radiation therapy with curative intent for the current breast cancer * A previous definitive ipsilateral breast surgery for the current breast cancer * Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137). * Immunosuppressive drugs, including, but not limited to, prednisone or equivalent, methotrexate, azathioprine, and TNF-α antagonists at doses exceeding 10 mg per day. The following exceptions are allowed: * The use of immunosuppressive drugs for the treatment of study drug-associated AEs or the use of immunosuppressive drugs in subjects with contrast allergy is acceptable. * The use of inhaled, topical, and intranasal glucocorticoids is permitted. * Corticosteroids are allowed as a prophylactic drug for hypersensitivity reactions (eg, before CT or MRI). * Corticosteroids are allowed as antiphylactic and therapeutic agents for chemotherapy-induced vomiting. * Short-term use of glucocorticoids for underlying or intercur

Inclusion Criteria: * Age of 18-25 years * Understanding the Lithuanian language * Having access to a device for intervention delivery * Experiencing moderate levels of psychological distress (a cut-off score of 8 as measured with Kessler-6) Exclusion Criteria: * People at imminent risk of suicide * People currently experiencing a psychotic episode * People currently experiencing interpersonal violence * Current dependency on alcohol/drugs

Inclusion Criteria: * Diagnosis of at least one of the following conditions: hypertension, type 2 diabetes, hyperlipidemia, chronic kidney disease, and/or metabolic syndrome. * At least 18 years of age at the time of signing consent. * Participants must have reliable transportation to attend Exercise is Medicine sessions. * Access to an internet-enabled device. * No objections to online grocery shopping, home food deliveries, or nutrition counseling. * Residence meets Instacart delivery requirements (e.g., non-institutionalized). * Participant is willing to use a personal credit card for Instacart back-up payments. * Participants must speak English to be able to consent and engage in FIM and EIM programs. * Participant has been clinically prescribed GLP-1RA's. Exclusion Criteria: * Conditions that impact digestion, metabolism, or food intake (e.g. surgical loss of esophagus, stomach, or colon, pancreatic dysfunction, bariatric surgery, brain surgery that alters cognition, etc.). * Participants with uncontrolled mental illness disorders (e.g., schizophrenia, bipolar disorder, major depression, etc.) that are not well-managed or controlled through treatment, as determined by the study team. * Familial history of certain cancers (e.g., multiple endocrine neoplasia, medullary thyroid carcinoma, etc.). * Active digestive illnesses (i.e., Celiac disease, irritable bowel syndrome, chronic malabsorption). * Comorbidities such as psychiatric or general illness that may put the subject at risk as determined by the investigator/s. * Renal impairment, eGFR \< 60 ml/min/1.73m2 * Factor which, in the investigator's opinion, is likely to compromise the subject's ability to participate in the study. * Recent participation (e.g., 3 months) in other behavioral nutrition trials or programs (i.e., bariatric programs, diabetes education programs). * Currently pregnant or planning to become pregnant during the study. * Participant is not willing to provide a urine, blood, or stool sample.

Inclusion criteria * Male and female participants aged 18 years or older and able to understand and give written informed consent * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (for the phase I portion of the study) and ECOG performance status of 0-2 (for the phase II portion of the study) * Life expectancy of at least 3 months * Histologically confirmed metastatic TNBC. (Estrogen receptor \[ER\] ≤10%; Progesterone receptor \[PgR\] ≤10%, HER2-negative as per ASCO/CAP guidelines) * Willingness to provide archival tumor tissue for correlative studies associated with this trial. * Received at least 1 prior line of systemic chemotherapy for metastatic TNBC and/or meet criteria to receive sacituzumab govitecan as standard of care * Measurable disease by CT or MRI as per RECIST Version 1.1 criteria * Adequate organ and marrow function as defined below: 2\. Exclusion Criteria Participants who meet any of the following exclusion criteria are not eligible to be enrolled in this study. * Positive serum pregnancy test or women who are lactating. * Known or severe (≥ Grade 3) hypersensitivity or allergy to naxitamab and/or sacituzumab govitecan, their metabolites, or formulation excipient. * Grade 3 or greater peripheral neuropathy * Have previously received treatment with an anti-GD2 antibody * Prior treatment with TROP2-targeting antibody drug conjugates in the metastatic setting. Participant s who have received TROP2-targeting antibody drug conjugates in the neoadjuvant setting or adjuvant setting are eligible if at least 6 months have elapsed since the last dose of TROP2-targeting antibody drug conjugate. * Have an active second malignancy. Participant s with a history of active cancer for 3 years prior to enrollment, or participant s with surgically cured tumors with low risk of recurrence (eg, nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll. * Have known active central nervous system (CNS) metastases and/or carcinomatous meningitis. * Have undergone an allogenic tissue or solid organ transplant. * Uncontrolled hypertension, defined as a consistently elevated systolic blood pressure of \>160 mmHg despite optimal medical management * Clinically significant cardiac disease * Inadequate pulmonary function * Active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment. * Uncontrolled seizure disorders despite anticonvulsant therapy (defined as a seizure event within 3 months prior to enrollment) * Active serious infection requiring systemic antimicrobial therapy. * Participants positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease. * Have active hepatitis B or C infection * Has a diagnosis of immunodeficiency or receiving systemic corticosteroid therapy (higher than physiologic doses) ≥ 10 mg of prednisone per day or equivalent\] or any other form of immunosuppressive therapy within 14 days of initiation of study treatment. * Has received prior radiotherapy within 1 weeks of start of study intervention.

* Quantitative Phase * Inclusion Criteria: Women over 18 years of age, or with parental or legal guardian consent. At least one of the following criteria: Women undergoing their first nipple-areola complex (NAC) reconstruction through micropigmentation and/or: No previous neo-nipple surgery, either unilaterally or bilaterally. Surgical reconstruction of the areola. Surgical reconstruction of the NAC with subsequent retraction of the neo-nipple. More than 6 months since their last surgery. \- Exclusion Criteria: Allergy to hyaluronic acid. Poor tolerance to needle injections. Withdrawal Criteria: Participant's voluntary decision. Complications associated with the technique (allergy, hematoma, etc.). Clinical deterioration preventing the woman from continuing in the study. \- Qualitative Phase Participant Profile Characteristics: For the qualitative phase, women who have received NAC reconstruction with HA will be invited to participate, following the maximum variation criterion. To ensure the inclusion of participants with diverse characteristics and capture a wide range of perspectives and experiences on the phenomenon under study, women of varying ages, with different breast cancer diagnoses, and histories of various oncological, surgical, and therapeutic treatments will be selected.

Inclusion Criteria: * A woman over 18 years old in the first trimester of pregnancy (11th-13th gestational week) * Signed the Consent to Participate in the Project and GDPR. Exclusion Criteria: * Unsigned the Consent to Participate in the Project and the Consent to the Processing of Personal Data.

Inclusion Criteria: All patients who: * are ≥18 years of age * have a recorded clinical diagnosis of asthma (ICD-10 Code: J45) * meet the requirements for treatment of severe T2-high asthma for Dupilumab defined as: * FeNO \> 25 ppB * two measurements of at least 250 eosinophils /µl in the blood OR one measurement of blood eosinophils at least 250 cells/µl during reduction of OCS dosing if treated with oral corticosteroids and/or one measurement of sputum ≥ 2% or BAL eosinophils ≥ 1% * have a history of treatment with monoclonal antibodies for asthma if a wash out period of 2 half-lives or 1 month (whatever is longer) has passed Exclusion Criteria: Patients who: * are pregnant as determined by a ß-HCG test * have severe anatomic variations or deviations that do not allow bronchoscopy * suffer from additional others confounding underlying lung disorder including but not limited to: Bronchiectasis, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, emphysema, Cystic fibrosis, any known parasitic infections and lung cancer. * show pulmonary conditions with symptoms of asthma and blood eosinophilia, including but not limited to: Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis, hypereosinophilic syndrome * suffer from a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, * have clinically meaningful comorbidity as determined by the evaluating committee, * experience of an asthma exacerbation within 4 weeks prior to the first main visit * immune disorder and/or immunosuppressive treatment (e.g. cyclosporine), ongoing biological treatment of asthma (e.g., mepolizumab, omalizumab, benralizumab) or last biological treatment 2 half-lives or 1 month before the first main visit * have a history of drug and alcohol abuses * are currently smoking or are former smokers for less than 6 months with \>10 pack years

Inclusion Criteria: For Adolescent Participants 1. Adolescents ages 13 to 17 years. 2. Adolescents must be English-speaking. 3. Legal guardian permission (informed consent) and child consent/assent. 4. A score of 5-10 on the Patient Health Questionnaire 9-Item: Modified for Teens (PHQ-9-M) at the primary care well-visit. 5. Access to a phone, computer, or other electronic device that could be used for study activities For Legal guardian Participants 1. Legal guardian of an adolescents ages 13 to 17 years who scored 5-10 on the PHQ-9-M at the primary care well-visit. 2. Consent to participate. 3. English-speaking. 4. Access to a phone, computer, and/or tablet to complete remote evaluations. Exclusion Criteria: Exclusion criteria will be determined based on electronic health record (EHR) review, eligibility screening questions, the baseline evaluation, and any other interactions with the family. 1. Suicidal ideation or behaviors reported on the PHQ-9-M at their well-visit (score of 1 or higher on item 9 "In the past week, have you had thoughts that you would be better off dead, or of hurting yourself in some way?" and/or yes to either of the supplemental questions which ask, "Has there been a time in the past month when you have had serious thoughts about ending your life?" and "Have you ever, in your whole life, tried to kill yourself or made a suicide attempt?") based on medical record review. For the PHQ-9-M administered at baseline, adolescents who mark yes to the supplemental item about serious suicidal ideation in the past month ("Has there been a time in the past month when you have had serious thoughts about ending your life?") will be excluded. 2. Major medical illness, significant behavioral problems or intellectual or developmental disabilities that may interfere with the completion of all study procedures. 3. Youth may be excluded on a case-by-case basis if the EHR review, eligibility screener, baseline evaluation, or other interactions with the family suggests that the group program would not be appropriate.

Inclusion Criteria: * 18 years of age or older * Current or former paid or volunteer PSP * Living in a province in Canada where PSPNET offers the Sleep Couse for the treatment period * Willingness to learn information and skills to self-manage sleep difficulties * Have internet access * Consent to Sleep Course, online therapy as provided by PSPNET, and associated research Exclusion Criteria: * Current severe medical or psychiatric disorder (e.g. current and recent mania or psychosis, recent hospitalization for mental health concerns, actively suicidal, medical condition client thinks will interfere with treatment, severe substance use) * Unable to read and understand English. (All content is provided in English and staff is English speaking; pending findings of the research PSPNET will explore translating the course into French)

Inclusion criteria * According to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition) from department of medical administration, nation health commission of the People's Republic of China, with any one of the following high-risk factors for liver cancer: hepatitis B and/or C virus infection, excessive alcohol consumption, hepatic steatosis or metabolic dysfunction-associated liver disease, dietary exposure to aflatoxin B1, liver cirrhosis from other causes, or a family history of liver cancer, and an aMAP score (age⁃male⁃albi⁃platelets score) of 60-100 points. * Liver disease patients with no evidence of suspected liver cancer in any imaging examination (liver US, contrast-enhanced CT, or contrast-enhanced MRI) within the past six months. * Signed informed consent form. Exclusion Criteria: * History of previous liver cancer diagnosis. * Baseline screening at enrollment diagnosed with liver cancer. * Child-Pugh score ≥ 10 (class C). * History of other malignant tumors. * Pregnant or lactating women. * Clinically diagnosed severe heart/lung disease or uncontrolled comorbidities, with investigator-judged life expectancy \< 2 years. * Glomerular filtration rate \< 50 mL/min. * Inability to undergo (enhanced) MRI due to contraindications or relative contraindications. * Poor compliance or unsuitability for the clinical trial as judged by the investigator.

Inclusion Criteria: * parent of a child with medical complexity aged 1-18 * able to communicate in Chinese and read Chinese * willing to participate in face-to-face activities Exclusion Criteria: * a reported mental health disorder * engaging in other psychosocial educational programs related to stress reduction * inability to communicate in Cantonese

Inclusion Criteria: * Patient 18 years or older with breast cancer and biopsy-proven malignant involvement of an axillary lymph node * Surgical management will be determined by the surgeon, who will decide if preoperative Iodine (I)-125 seed localization of the positive node is necessary or if they will retrieve the positive node with intraoperative ultrasound guidance. During surgery, the targeted node, its associated biopsy markers, I-125 seed if placed, and optimized twinkling marker will be resected. The position of the marker in the lymph node or proximity to the node will be noted from the surgical and pathology documentation * Surgery will be performed by one of the surgeons in the Division of Breast and Melanoma Surgical Oncology (Doctor \[Dr.\] Judy Boughey, Dr. Amy Degnim, Dr. Tina Hieken, Dr. Jeffrey Johnson, Dr. Mary Mrdutt, Dr. Shon Black) * Patients must be able to understand the study procedures and comply with them for the entire length of the study * No contraception is necessary or required Exclusion Criteria: * Patients who are pregnant * Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements * Current or past participation within a specified timeframe in another clinical trial, as warranted by the administration of this intervention

Inclusion Criteria: 1. Confirmed diagnosis of ectopic pregnancy, aged ≥18 years, and with normal psychological status. 2. Patients planned to undergo single-port laparoscopic surgery under general anesthesia, followed by postoperative patient-controlled intravenous analgesia (PCIA). 3. Patients classified as ASA I or II. 4. Able to understand the study process and methods, voluntarily participate, and sign the informed consent form. Exclusion Criteria: 1. Patients using other analgesic methods or multiple analgesic approaches. 2. Patients with a history of allergies or allergies to anesthetic drugs. 3. Patients with a history of depression or mental illness. 4. Patients with other severe organ dysfunction. 5. Patients unable to operate the intravenous analgesia pump independently.

Inclusion criteria 1. Males or females, 20 years of age or older 2. Diagnosis of open angle glaucoma (OAG) in the study eye 3. Iridocorneal angle grade 3 (open, 20-35 degrees) or grade 4 (wide open, 35-45 degrees) according to Shaffer Angle Grading System in all quadrants of the study eye. (For subject's undergoing combined cataract extraction (with IOL implantation) with MINIject implantation, a grade 2 angle is acceptable prior to cataract surgery so long is the angle becomes grade 3 or greater prior to MINIject implantation). 4. Glaucoma not adequately controlled with at least one topical hypotensive medication(s), unless the subject has an allergy / intolerance to a medication or inability to consistently access medication. Examples include but are not limited to prostaglandins, beta blockers, carbonic anhydrase inhibitors or alpha-2-agonists 5. Minimal visual acuity in the study eye must be 35 letters EDTRS (20/200) or better and 50 letters ETDRS (20/100) or better in the fellow eye 6. Maximal C/D ratio must be 0.9 in the study eye 7. Subjects must be willing and able to follow study instructions and to return for scheduled study-related examinations 8. Subjects must provide written informed consent prior to any study procedures 9. Part 2 Only: Operable age-related cataract eligible for phacoemulsification surgery with Intraocular Lens (IOL) implantation 10. Part 2 Only: The following intraoperative criteria following the IOL implantation need to be met in order for investigator to proceed with the investigational device placement: 1. Capsulorhexis is intact and centered 2. Posterior capsular bag is intact 3. The IOL is well-centered in the capsular bag 4. There is no evidence of zonular dehiscence/rupture 5. The Anterior Chamber (AC) angle was able to be clearly visualized using direct gonioscopy. Exclusion criteria Subjects are not eligible for inclusion in this clinical investigation if one or more of the following criteria are met: 1. Grade 2 (narrow, 20 degrees), grade 1 (extremely narrow, less or equal to 10 degrees) and grade 0 (closed or slit) iridocorneal angle according to Shaffer Angle Grading System in the study eye except for the situation described in inclusion criterion #3. 2. Any eye surgery that was performed \< 90 days before Screening/Baseline visit in the study eye 3. Diagnosis of diabetes mellitus with HbA1C \>7% 4. Known or suspected allergy or hypersensitivity to medical silicone 5. Allergy to fluorescein 6. Corneal opacity or iridocorneal angle not visible through gonioprism in the study eye, preventing correct placement of the implant 7. Central endothelial cell density (ECD) at Screening visit with a mean value \<1900 cells/mm2 or coefficient of variation (CV) of endothelium \>0.45 A variance of 5% less than this cell count is permitted if in the clinical judgement of the Investigator the potential benefit/risk to subject participation is favorable and the central corneal endothelial morphology is characterized as normal by the usual criteria of hexagonality, polymorphism, and polymegathism 8. Anticipated need for ocular surgery or retinal laser procedure in the study eye 9. Anterior chamber anatomic configuration of high risk for development of angle closure glaucoma in the study eye, 10. Pre-existing ocular or systemic pathology that, in the opinion of the investigator (reason to be specified on the case report form), is likely to cause post-operative complications following implantation 11. Central corneal thickness greater than 600 microns 12. Clinically significant degenerative visual disorders that, in the opinion of the investigator, can impact study examinations (e.g. exudative macular degeneration or other retinal disorders) 13. Clinically significant corneal disease (e.g., corneal dystrophy) in the study eye 14. Evidence of crystalline lens subluxation or luxation in the study eye 15. Inability to perform Visual Field (VF) testing in either eye 16. Evidence of vitreous loss in the anterior chamber in the study eye 17. Clinically significant intra-ocular inflammation or infection 18. Presence of silicone oil in the study eye 19. Participation in any study involving a drug or device within the past 3 months and planned participation to any other study during the present study. There is no exclusion period after completion of the present trial 20. Only for women of childbearing potential: positive pregnancy test at Screening/Baseline visit. Pregnant or lactating women 21. Subject is under tutorship or trusteeship 22. Subject has a condition such that his / her ability to provide personal informed consent is compromised 23. Diagnosis of cataract in the study eye that is not age-related e.g., traumatic, inflammatory or resulting from diabetes in the study eye 24. Unable to discontinue anticoagulant/antiplatelet therapy (i.e. acetylsalicylic acid, coumadin, heparin, apixaban, etc.) for the surgical procedure. The amount of washout and when to restart therapy after surgery is at the Principal Investigator's discretion and may be based on literature references (see Annexes) or in consultation with the subject's primary care team.

Inclusion Criteria: * Inuit * Able to consent to study participation * Participating in community wellness programs facilitated by the Aqqiumavvik Wellness Centre within 6 months prior to screening * Willing to consume country foods provided as part of the intervention * Willing to engage in individual and group activities, including guided conversations and cultural workshops * 18-65 years of age Exclusion Criteria: * Less than 18 years of age * Greater than 65 years of age * Unable to consent to study participation * Mental health conditions requiring immediate clinical intervention * Known allergies or medical conditions that prevent the consumption of traditional country foods * Physical or logistical barriers that prevent participation in weekly activities

Inclusion Criteria: * Availability of documented or estimated date of first symptom suggestive of PAH. * Availability of documented date of confirmed PAH diagnosis. Exclusion Criteria: * Patients with pulmonary hypertension not classified as Group 1 (e.g., due to left heart disease, chronic lung disease, or chronic thromboembolic disease). * Patients with insufficient data to determine either the date of symptom onset or the date of confirmed diagnosis. * Patients diagnosed only clinically or by echocardiography, without confirmation by right heart catheterization.

Inclusion Criteria: * (1) adults who aged between 18-40 * (2) without any mental diagnosis * (3) able to speak and read Mandarin, Cantonese, or English * (4) moderate stress or problems in academic activities, problems in interpersonal relationships, or adaptability to college life. * (5) participants DASS-21 score \>= "Moderate" severity on each subscale (Depression \>= 14; Anxiety \>= 10; Stress \>= 19). Exclusion Criteria: * (1) has more than 10 consecutive years professional music training * (2) with chronic illness and taking medication * (3) with prior history of brain trauma or brain surgery * (4) wearing metal piercings or implants.

Inclusion Criteria: 1. Presence of depression attributed to cancer itself or cancer-related treatments, meeting the diagnostic criteria for depressive disorder（DSM-V). 2. Age between 18 and 75 years, regardless of sex. 3. Hamilton Depression Rating Scale-17 (HDRS-17) total score \>17 at baseline. 4. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2. 5. No previous exposure to acupuncture treatment. 6. Ability to understand the study procedures and willingness to provide written informed consent. Exclusion Criteria: 1. Planned to undergo surgery, chemotherapy, radiotherapy, immunotherapy, or other active cancer-related treatments during the study period. 2. History of major depressive episodes prior to cancer diagnosis. 3. Pain Rating Index (PRI) score ≥4 due to cancer-related pain. 4. Estimated life expectancy of 12 months or less. 5. Presence of severe ulcers, abscesses, or active skin infections at or near the acupuncture sites. 6. Clinically significant dysfunction of major organs, including severe cardiac, cerebral, hepatic, renal impairment; decompensated pulmonary disease; or other serious systemic illnesses. 7. Pregnant or breastfeeding women. 8. Participation in another clinical trial within the past 30 days. 9. Patients with a cardiac pacemaker or other implanted electronic medical devices.